Ritlecitinib
Brand names: Litfulo · Active ingredient: Ritlecitinib Tosylate
In short: LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
What is Ritlecitinib used for?
LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.
Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
âš Boxed warning (FDA's strongest warning)
•
Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment if serious infection occurs until the infection is controlled. LITFULO should not be given to patients with active tuberculosis. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. (5.1)
•
Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. LITFULO is not approved for use in RA patients. (5.2)
•
Malignancies have occurred in patients treated with LITFULO . Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients. (5.3)
•
Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. (5.4)
•
Thrombosis has occurred in patients treated with LITFULO. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. (5.5)
Ritlecitinib dosage
Perform the following evaluations prior to LITFULO initiation:
•Tuberculosis (TB) infection evaluation: LITFULO initiation is not recommended in patients with active TB. For patients with latent TB or those with a negative latent TB test who are at high risk for TB, start preventive therapy for latent TB prior to initiation of LITFULO .
•Viral hepatitis screening in accordance with clinical guidelines: LITFULO initiation is not recommended in patients with hepatitis B or hepatitis C .
•Treatment with LITFULO should not be initiated in patients with an absolute lymphocyte count (ALC) <500/mm3 or a platelet count <100,000/mm3
.
•Update immunizations according to current immunization guidelines .
The recommended dosage of LITFULO is 50 mg orally once daily with or without food .
Swallow capsules whole. Do not crush, split, or chew LITFULO capsules.
If a dose is missed, administer the dose as soon as possible unless it is less than 8 hours before the next dose, in which case, skip the missed dose. Thereafter, resume dosing at the regular scheduled time.
LITFULO is not recommended in patients with severe (Child Pugh C) hepatic impairment .
If treatment interruption is indicated, a temporary treatment interruption for less than 6 weeks is not expected to result in significant loss of regrown scalp hair.
Hematologic Abnormalities
Recommendations for LITFULO treatment interruption or discontinuation for hematologic abnormalities are summarized in Table 1.
Laboratory Measure | Recommendation
ALC = absolute lymphocyte count.
Platelet Count | Treatment should be discontinued if platelet count is <50,000/mm3
Lymphocytes | Treatment should be interrupted if ALC is <500/mm3 and may be restarted once ALC return above this value.
ALC and platelet counts are recommended before treatment initiation and at 4 weeks after treatment initiation, and thereafter according to routine patient management .
How to take Ritlecitinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Administration
Advise patients not to crush, split or chew LITFULO capsules .
Serious Infections
Inform patients that they may develop infections when taking LITFULO which in some cases can be serious. Instruct patients to tell their healthcare provider if they develop any signs or symptoms of an infection .
Advise patients that the risk of herpes zoster is increased in patients treated with LITFULO .
Malignancies
Inform patients that LITFULO may increase their risk of certain cancers, including skin cancers. Periodic skin examinations are recommended while using LITFULO .
Thromboembolic Events
Advise patients that events of PE and retinal artery occlusion have been reported in clinical trials with LITFULO. Instruct patients to seek immediate medical attention if they develop any signs or symptoms of a thrombosis .
Hypersensitivity Reactions
Advise patients to discontinue LITFULO and seek immediate medical attention if they develop any signs and symptoms of serious allergic reaction . …
Warnings & precautions
Do not take this medicine if: LITFULO is contraindicated in patients with known hypersensitivity to ritlecitinib or any of its excipients .
Serious infections have been reported in patients receiving LITFULO. The most frequent serious infections have been appendicitis, COVID-19 infection (including pneumonia), and sepsis . Among opportunistic infections, multi-dermatomal herpes zoster was reported with LITFULO.
Avoid use of LITFULO in patients with an active, serious infection. Consider the risks and benefits of treatment prior to initiating LITFULO in patients:
•with chronic or recurrent infection
•who have been exposed to TB
•with a history of serious infection or an opportunistic infection
•who have resided or traveled in areas of endemic TB or mycoses, or
•with underlying conditions that may predispose them to infection
Closely monitor patients for the development of signs and symptoms of infection during and after treatment with LITFULO. Interrupt LITFULO if a patient develops a serious or opportunistic infection. A patient who develops a new infection during treatment with LITFULO should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient, appropriate antimicrobial therapy should be initiated, and the patient should be closely monitored. LITFULO may be resumed once the infection is controlled.
Tuberculosis
Screen patients for tuberculosis (TB) before starting therapy. LITFULO should not be given to patients with active TB. Anti-TB therapy should be started prior to initiating therapy with LITFULO in patients with a new diagnosis of latent TB or previously untreated latent TB. In patients with a negative latent TB test, consider anti-TB therapy before initiating treatment with LITFULO in those at high risk and consider screening patients at high risk for TB during treatment with LITFULO. …
Ritlecitinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
•Serious Infections
•Malignancy and Lymphoproliferative Disorders
•Thromboembolic Events
•Hypersensitivity
•Laboratory Abnormalities
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of LITFULO was evaluated in three randomized, placebo-controlled clinical trials and one long-term trial in subjects with alopecia areata, including alopecia totalis and alopecia universalis, who were 12 years of age and older. A total of 1628 subjects were treated with LITFULO representing 2085 subject-years of exposure. There were 1011 subjects with at least 1 year of exposure to LITFULO. In the placebo-controlled period of clinical trials in alopecia areata, a total of 668 subjects were exposed to LITFULO with 130 receiving 50 mg once daily for up to 24 weeks. The median age of subjects was 33 years, 105 (11.9%) subjects were 12 to <18 years old and 22 (2.5%) subjects were 65 years of age or older. The majority of subjects were White (70.7%) and female (63.6%).
Adverse reactions occurring at ≥1% in the treated groups and at a higher rate than placebo are presented in Table 2. …
Drug interactions
Table 3 includes clinically significant drug interactions affecting other drugs.
CYP3A Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions
Clinical Impact | Ritlecitinib is a CYP3A inhibitor. Concomitant use of ritlecitinib increases AUC and Cmax of CYP3A substrates , which may increase the risk of adverse reactions of these substrates.
Intervention | Consider additional monitoring and dosage adjustment in accordance with approved product labeling of CYP3A substrates where small concentration changes may lead to serious adverse reactions when used with LITFULO.
CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions
Clinical Impact | Ritlecitinib is a CYP1A2 inhibitor. Concomitant use of ritlecitinib increases AUC and Cmax of CYP1A2 substrates , which may increase the risk of adverse reactions of these substrates.
Intervention | Consider additional monitoring and dosage adjustment in accordance with the approved product labeling of CYP1A2 substrates where small concentration changes may lead to serious adverse reactions when used concomitantly with LITFULO.
Table 4 includes clinically significant drug interactions affecting LITFULO. …
About this medicine
LITFULO (ritlecitinib) capsules are formulated with ritlecitinib tosylate, a kinase inhibitor.
Ritlecitinib tosylate is a white to off white to pale pink solid which is freely soluble in water. The chemical name is 1-{(2S,5R)-2-Methyl-5-[(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}prop-2-en-1-one 4-methylbenzene-1-sulfonic acid.
The molecular formula for ritlecitinib tosylate is C22H27N5O4S. The molecular weight is 457.55 g/mol and its structural formula is:
LITFULO is supplied for oral administration as a 50 mg immediate-release capsule. Each capsule contains 50 mg ritlecitinib (equivalent to 80.13 mg ritlecitinib tosylate) and the following inactive ingredients: crospovidone, glyceryl dibehenate, lactose monohydrate, microcrystalline cellulose, and hypromellose (HPMC) capsule shells. The yellow/blue, opaque capsule shells contain Brilliant blue FCF – FD&C Blue, hypromellose, titanium dioxide, and yellow iron oxide.
How it works: LITFULO is a kinase inhibitor. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1882f799-61b0-4813-965a-4910c4ae419c. Read the full official label on DailyMed.